"VCs dole out $5.49 billion during the third quarter, but invest less money in each company.
Venture capitalists invested 9.4 percent more in high-tech startups during the third quarter than they did a year earlier, according to a study released Monday, but the typical deal was smaller.
The total investment rose to $5.49 billion from $5.02 billion in Q3 2004, according to the study by VentureOne. The median amount invested in each startup that received financing during the quarter fell 4.6 percent to $6.7 million from $7 million during the same period last year.
Investment in information technology startups increased 10.6 percent to $3.11 billion, up from $2.81 billion in the third quarter of 2004.
Venture capital interest in healthcare cooled as VCs put 2.8 percent less money into biotechnology, pharmaceuticals, and medical devices. Investment fell to $1.66 billion, down from $1.71 billion during last year’s third quarter.
Consumer product startups saw the biggest uptick in venture backing. Investment increased 443.3 percent, closing the quarter at $36.4 million, up from $6.7 million.
Biopharmaceuticals posted the biggest loss, losing 19.7 percent of their funding to close the third quarter at $907 million, down from $1.13 billion.
Early-Stage Anxiety
Seed and first-round investment fell 7.3 percent to $1.18 billion during the third quarter, down from $1.28 billion during the same period last year.
Yet the deal flow edged up slightly. Early-stage deals accounted for 35 percent of all VC investments, up from 34 percent in 2004. “This is a clear sign that investors still support early-stage innovative growth companies,” said John Gabbert, vice president of VentureOne.
But many deals may not be counted, say investors. “For early-stage investing, the numbers may not accurately reflect what’s going on,” said Wes Raffel, a venture capitalist with Advanced Technology Ventures. “We’re seeing more early-stage opportunities. Our calendars are fuller now.”
But along with better deal opportunities comes less disclosure about investment activity, especially in the early stages. When one VC hears about an interesting company, he or she may bid up the company’s valuation.
“It’s getting very competitive and expensive,” said early-stage investor Venky Ganesan, managing director of Globespan Capital Partners.
Increased competition is keeping some VCs from saying anything about their investments, even to reporting agencies such as VentureOne.
“Ten percent of our portfolio has not given any information about what they are doing,” said Mr. Raffel.
Mr. Ganesan said his firm keeps all of its seed and first-round investments secret.
Although early-stage venture firms may be keeping their cards close to their chests, angel investors have been more active. Innovators who meet with angels are twice as likely to receive funding this year compared to two years ago, according to one study.
In 2005, angel investors backed 21.8 percent of the companies they investigated, up from 10.3 percent in 2003, according to a study by the Center for Venture Research (see Angels Fund More Deals in ’05)."